Comparative analysis of early treatment effectiveness of first-line disease-modifying therapies and fingolimod on cognitive functions in persons with multiple sclerosis

被引：0
|
作者：
Yigit, P. [1 ]
Sagici, O. [1 ]
Abasiyanik, Z. [1 ]
Baba, C. [1 ]
Ozakbas, S. [2 ]
机构：
[1] Dokuz Eylul Univ, Grad Sch Hlth Sci, Izmir, Turkey
[2] Dokuz Eylul Univ, Dept Neurol, Fac Med, Izmir, Turkey
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P658
引用
收藏
页码：566 / 567
页数：2
相关论文
共 50 条
  • [1] Effects of first-line and second-line disease-modifying therapies on cognitive function in persons with multiple sclerosis
    Ozakbas, Serkan
    Yigit, Pinar
    Sagici, Ozge
    Ozdogar, Asiye Tuba
    Abasiyanik, Zuhal
    Kahraman, Turhan
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (07) : 1052 - 1053
  • [2] First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis A Comprehensive Overview
    Johnston, Jessica
    So, Tsz-Yin
    [J]. DRUGS, 2012, 72 (09) : 1195 - 1211
  • [3] Changes in cognitive functions after disease-modifying therapies switching in persons with multiple sclerosis
    Ozakbas, Serkan
    Yigit, Pinar
    Sagici, Ozge
    Ozdogar, Asiye Tuba
    Abasiyanik, Zuhal
    Kahraman, Turhan
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (07) : 1050 - 1050
  • [4] Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis
    Earla, Jagadeswara R.
    Hutton, George J.
    Thornton, Douglas J.
    Chen, Hua
    Johnson, Michael L.
    Aparasu, Rajender R.
    [J]. PHARMACOTHERAPY, 2021, 41 (05): : 440 - 450
  • [5] Discontinuation of first-line disease-modifying therapy in multiple sclerosis
    Coerver, E. M.
    Bourass, A.
    Wessels, M. H.
    Van Kempen, Z. L.
    Jasperse, B.
    Barkhof, F.
    Mostert, J.
    Uitdehaag, B. M.
    Killestein, J.
    Strijbis, E. M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 338 - 338
  • [6] Predictors of Response to First-Line Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
    Castillo-Trivino, Tamara
    Gajofatto, Alberto
    Bacchetti, Peter
    Waubant, Emmanuelle
    [J]. NEUROLOGY, 2010, 74 (09) : A155 - A155
  • [7] RELAPSE-RELATED OUTCOMES IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH FIRST-LINE DISEASE-MODIFYING THERAPIES
    Cohan, S.
    Corvino, F. A.
    Oliveri, D.
    Heo, J. H.
    Wang, W.
    Tencer, T.
    [J]. VALUE IN HEALTH, 2019, 22 : S737 - S737
  • [8] Comparison of Adherence and Persistence Associated with First-Line Disease-Modifying Therapies among Patients with Multiple Sclerosis
    Halpern, Rachel
    Agarwal, Sonalee
    Borton, Leigh A.
    Babic, Tomislav
    [J]. NEUROLOGY, 2010, 74 (09) : A547 - A548
  • [9] Comparative Effectiveness Among the First-line Disease Modifying Therapies Multiple Sclerosis Relapse - A Nationwide Observational Study in Taiwan
    Chou, Chih-Ho
    Lin, Tzu-Chieh
    Cheng, Ching-Lan
    Yang, Yea-Huei Kao
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (03) : 393 - 393
  • [10] First-Line Disease-Modifying Therapies in Paediatric Multiple SclerosisA Comprehensive Overview
    Jessica Johnston
    Tsz-Yin So
    [J]. Drugs, 2012, 72 (9) : 1195 - 1211
12345